#sleep apnea

3개의 글

August 1, 2026

INSP (Inspire Medical) Stock Outlook 2026: The Sleep Apnea Implant Moat vs. the GLP-1 Shadow

INSP (Inspire Medical Systems) 2026 stock outlook. A deep qualitative look at the hypoglossal nerve stimulation implant for obstructive sleep apnea (OSA), the razor-and-blade growth model, the clinical-evidence and reimbursement and hospital-adoption moat, CPAP-intolerant market penetration, the GLP-1 weight-loss threat, Nyxoah competition, and the path to profitability.

INSP Inspire Medical sleep apnea

June 25, 2026

Philips CPAP Recall Lawsuit 2026 — Who Qualifies, Settlement Tracks & Payout Structure

Philips Respironics CPAP, BiPAP and ventilator recall lawsuit 2026 — the 2021 Class I recall, degrading PE-PUR foam and cancer concerns, how the personal injury MDL differs from the economic loss and medical monitoring class settlements, eligibility, proof, fees, and the statute of limitations for U.S. claimants.

Philips CPAP CPAP recall PE-PUR foam

May 29, 2026

RMD ResMed Stock Outlook 2026: GLP-1 Fear Is Overdone, Here's the Real Math

ResMed (NYSE: RMD) stock analysis — AirSense 11 platform, Philips recall windfall locked in, GLP-1 impact with real adherence data, Brightree/MatrixCare SaaS margin lift. TTM revenue $5.54B, FCF $1.75B. Bull case, bear case, and where we stand.

RMD ResMed sleep apnea